Neothetics (NEOT) is on the road now to fund the continued development of their injection-based approach to fat loss. It's a smallish deal of 4.3M shares with a $13-15 price range. Three mid-market banks: Piper Jaffray, Guggenheim and Needham are on the cover. Post-IPO there will be ~14M shares outstanding for a market capitalization of ~$200M at the mid-point of the range. [A transcript of the IPO roadshow is in process but the NEOT IPO roadshow slides are available.]
Neothetics aims at the midsection of "thin people . . .